Catalyst Event
Gilead Sciences Inc (GILD) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
4/29/2026, 12:00:00 AM
The U.S. FDA accepted Gilead's New Drug Application (NDA) for its once-daily single-tablet HIV treatment combination, bictegravir/lenacapavir, and granted it priority review with a PDUFA action date set for August 27, 2026, which is scheduled. High importance is estimated as this is a key pipeline milestone.
Korean Translation
미국 FDA가 길리어드의 1일 1회 단일정 HIV 치료제 복합제인 빅테그라비르/레나카파비르에 대한 신약 허가 신청(NDA)을 접수하고, 우선 심사 대상으로 지정함. PDUFA 결정일은 2026년 8월 27일로 예정됨. 주요 파이프라인 마일스톤으로서 중요도를 'High'로 예상함.
Related Recent Events
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q3 2026 earnings release scheduled.
10/15/2026, 12:00:00 AM
ASML Holding NV (ASML) · Earnings Release
ASML is scheduled to release its Q2 2026 financial results on 2026-07-15. The company guided for Q2 sales between €8.4 billion and €9.0 billion, with an estimated price impact of ≥5%, scheduled.
7/15/2026, 12:00:00 AM
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q2 2026 earnings release scheduled.
7/14/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Other
2026 Annual Meeting of Stockholders to be held virtually on 2026-06-17. Medium importance due to ≥5% price impact scheduled.
6/17/2026, 12:00:00 AM
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release, which typically results in a medium price impact of 5%, is scheduled.
6/11/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Q1 fiscal 2027 earnings release scheduled for 2026-06-09. Analysts forecast EPS of $1.07. Low importance due to ≥1% price impact forecasted.
6/9/2026, 12:00:00 AM